Clinical Trials for Sarcoma

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory histiocytic neoplasms (including ECD, LCH, histiocytic sarcoma, Rosai-Dorfman) lacking actionable BRAF/MAP2K alterations or post–BRAF/MEK, plus high‑risk MDS/CMML/MF post‑standard therapy, and multiple relapsed/refractory lymphomas/CLL after ≥2 prior lines, receive oral Q702 (adrixetinib), a TAM kinase (AXL/MERTK) and CSF1R inhibitor given week-on/week-off. The trial assesses safety, RP2D, and preliminary efficacy across disease-specific cohorts.

ClinicalTrials.gov ID: NCT06712810

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin (Doxil®) in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable soft tissue sarcoma—emphasis on leiomyosarcoma—after prior therapy (including limited prior anthracycline) receive oral peposertib (DNA-PK inhibitor targeting NHEJ repair) continuously with low-dose pegylated liposomal doxorubicin every 28 days. Includes dose escalation across selected STS subtypes and a leiomyosarcoma expansion; requires biopsy-amenable disease, allows treated/stable CNS metastases, and excludes significant cardiac dysfunction and prior DNA-PK inhibitor exposure.

ClinicalTrials.gov ID: NCT05711615

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults with relapsed/refractory solid tumors—phase II focused on neuroblastoma and Ewing sarcoma—receive silmitasertib, an oral CK2 inhibitor (modulates PI3K/AKT and DNA damage response), combined with standard salvage chemotherapy backbones. Regimens include silmitasertib + irinotecan/temozolomide for neuroblastoma and silmitasertib + vincristine/irinotecan/temozolomide for Ewing sarcoma.

ClinicalTrials.gov ID: NCT06541262

Phase I Clinical Trial of Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Children and Young Adults With Relapsed or Refractory Solid Tumor Expressing B7-H3 Target

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults (2–30 years) with relapsed/refractory solid tumors (e.g., neuroblastoma, sarcomas, Wilms tumor) after standard therapy receive lymphodepleting fludarabine/cyclophosphamide followed by a single IV infusion of autologous B7-H3–directed CAR T cells (targets CD276). B7-H3 expression testing is required on tissue (positivity not mandatory); key exclusions include uncontrolled infection, active viral hepatitis/HIV, recent significant cardiac disease, untreated brain metastases, and need for systemic immunosuppression.

ClinicalTrials.gov ID: NCT06500819

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling pediatric (1 to <18 years) and young adult patients with relapsed/refractory B-ALL, DLBCL/Burkitt lymphoma, neuroblastoma, or Ewing sarcoma to receive single‑agent zilovertamab vedotin IV every 21 days in dose-escalation/expansion cohorts. Zilovertamab vedotin is a ROR1‑targeted antibody–drug conjugate delivering MMAE to tumor cells; primary aims are safety/PK and preliminary efficacy with disease‑specific response criteria.

ClinicalTrials.gov ID: NCT06395103

A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA‑A*02:01–positive unresectable or metastatic cutaneous melanoma (post–PD‑1) or synovial sarcoma needing further therapy receive autologous PRAME‑targeted TCR‑T cells (ACTengine IMA203) after lymphodepletion plus low‑dose IL‑2, combined with a PRAME mRNA vaccine (mRNA‑4203) to boost PRAME‑specific T‑cell responses. Key exclusions include active brain metastases, significant autoimmune/cardiac disease, prior allogeneic transplant, active viral infections, and hypersensitivity to study agents.

ClinicalTrials.gov ID: NCT06946225

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For children, adolescents, and young adults (≤21 years) with relapsed/refractory B7-H3 (CD276)–positive sarcomas (including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and other soft-tissue sarcomas) who have at least one lesion amenable to hypofractionated radiation. Treatment is hypofractionated radiation priming to ≥1 tumor site with fludarabine/cyclophosphamide lymphodepletion followed by IV infusion of autologous B7-H3–directed CAR T cells (genetically engineered T cells targeting the tumor antigen B7-H3).

ClinicalTrials.gov ID: NCT07222735

Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults (≥18) with metastatic or unresectable soft tissue sarcoma (RECIST-measurable, ECOG 0–1) who have progressed after 1–3 prior metastatic lines (ASPS allowed without prior refractoriness) and have had no prior PD-1/PD-L1/CTLA-4 therapy or zanzalintinib/cabozantinib. Treatment is oral zanzalintinib (XL092), a multikinase TKI targeting VEGFR2/MET/TAM (TYRO3/AXL/MER), combined with nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) induction, followed by maintenance nivolumab with ongoing daily zanzalintinib.

ClinicalTrials.gov ID: NCT06968988

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling children and adolescents aged 2 to <18 years with relapsed/progressive/refractory somatostatin receptor–positive malignancies (e.g., neuroendocrine tumors, CNS tumors, lymphoma, other solid tumors) after ≥1 prior therapy, requiring SSTR expression by IHC and uptake on SSTR PET/SPECT greater than liver. Patients receive IV lutetium Lu 177 edotreotide (177Lu-DOTATOC) peptide receptor radionuclide therapy—a radiolabeled somatostatin analog targeting SSTR2 to deliver localized beta radiation—every 8 weeks for up to 6 doses (with amino acids for renal protection), either as monotherapy or after standard-of-care therapy.

ClinicalTrials.gov ID: NCT06441331

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with previously untreated advanced unresectable or metastatic intermediate/high-grade soft tissue sarcoma receive physician-selected first-line systemic therapy plus oral extended-release metformin. Metformin is a biguanide with proposed anticancer activity via reduced insulin/IGF signaling and AMPK activation with downstream mTOR pathway inhibition.

ClinicalTrials.gov ID: NCT07291297